Immunotherapy for Cervical Cancer
Immunotherapy, particularly immune checkpoint inhibitors (ICI), has emerged as a major breakthrough in the treatment of cervical cancer, significantly expanding the therapeutic options beyond traditional approaches. While early-stage disease remains curable through radical surgery with adjuvant therapy, the integration of immunotherapy has transformed the management of advanced or recurrent disease by enhancing the immune system's ability to recognize and eliminate cancer cells.
-
Immunotherapy for Cervical Cancer (1)
GXF-111
Cat. No.: HY-153414
- Formula: C42H42ClN7O3
- Molecular Weight: 728.28
GXF-111 is a BRD3 and BRD4-L PROTAC degrader. Its BD1 and BD2 Ki values against human BRD3 are 11.97 nM and 2.45 nM, respectively. The degradation activity of GXF-111 depends on its binding to BET proteins and Cereblon, as well as the involvement of a functional proteasome. The degradation selectivity of GXF-111 is mainly determined by differences in degradation kinetics and cell types. GXF-111 induces G1 phase cell cycle arrest, downregulates c-Myc expression, upregulates p21 expression, and exhibits antiproliferative activity against a variety of cancer cell lines. GXF-111 can serve as a research tool for cancer-related studies.
